Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumorsBertrand Routy, Laurence Zitvogel, Solenn Brosseau et al.|Science|2017Cited by 5.4k
Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancerLisa Derosa, Benjamin Besse, Bertrand Routy et al.|Nature Medicine|2022Cited by 637
Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trialBertrand Routy, Saman Maleki Vareki, John Lenehan et al.|Nature Medicine|2023Cited by 446
Cross-reactivity between tumor MHC class I–restricted antigens and an enterococcal bacteriophageAurélie Fluckiger, Vincent Cattoir, Romain Daillère et al.|Science|2020Cited by 382
A Natural Polyphenol Exerts Antitumor Activity and Circumvents Anti–PD-1 Resistance through Effects on the Gut MicrobiotaMeriem Messaoudene, Bertrand Routy, Reilly Pidgeon et al.|Cancer Discovery|2022Cited by 225